Earnings Report for November 11, 2025: ALC, OKLO, DOX, CAE, ORLA, SMWB, HYLN, LPTH, STXS, PAL, EPM, QUIK Released After Market Hours
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Source: NASDAQ.COM
Earnings Reports Overview: Several companies, including Alcon Inc., Oklo Inc., and Amdocs Limited, are set to report their earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Alcon Inc. Performance: Alcon Inc. is expected to report earnings per share (EPS) of $0.77, a 4.94% decrease from the previous year, and has a Price to Earnings (P/E) ratio of 24.07, indicating potential growth compared to industry competitors.
Oklo Inc. and Other Companies: Oklo Inc. anticipates a significant EPS drop to -$0.13, while other companies like CAE Inc. and Similarweb Ltd. also project declines in EPS compared to the same quarter last year.
Mixed Results Across Sectors: Companies such as Proficient Auto Logistics and Evolution Petroleum Corporation are expected to show minimal changes or declines in EPS, reflecting a diverse range of financial health across different sectors.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like STXS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on STXS
Wall Street analysts forecast STXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STXS is 4.20 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.490
Low
4.00
Averages
4.20
High
5.00
Current: 2.490
Low
4.00
Averages
4.20
High
5.00
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stereotaxis Receives FDA Approval for MAGiC Magnetic Ablation Catheter
- FDA Approval: Stereotaxis announced it has received FDA approval for its MAGiC Magnetic Interventional Ablation Catheter, marking a significant advancement in surgical robotics and is expected to drive market demand for cardiac ablation therapies.
- Technological Innovation: The MAGiC catheter utilizes robotic navigation and computer-controlled magnetic fields to offer levels of precision and stability often unattainable with traditional catheters, aiming to improve treatment outcomes for complex patient populations, particularly those with arrhythmias.
- Market Expansion: This catheter is specifically designed for patients with anatomical abnormalities or prior surgical interventions that limit access via conventional manual catheter navigation, which is expected to significantly enhance the accessibility of minimally invasive cardiac ablation therapies to underserved patient populations.
- Strategic Implications: The FDA approval not only enhances Stereotaxis's competitiveness in the cardiac treatment space but also has the potential to generate new revenue streams, further solidifying its leadership position in the surgical robotics market.
Continue Reading
Stereotaxis Receives FDA Approval for MAGiC Catheter, Advancing Cardiac Treatment Technology
- FDA Approval Milestone: Stereotaxis's receipt of FDA approval for the MAGiC catheter marks a significant advancement in cardiac electrophysiology, enabling complex arrhythmia patients to benefit from robotic magnetic navigation technology, thereby enhancing the company's competitiveness in the medical device market.
- Technological Innovation: The MAGiC catheter is navigated by highly precise computer-controlled magnetic fields, offering maneuverability and stability levels often unattainable with traditional catheters, which is expected to significantly improve the safety and efficacy of cardiac ablation procedures.
- Market Potential: Designed for complex patient populations that are difficult to treat with conventional methods, the catheter is anticipated to expand Stereotaxis's market share in cardiac care, addressing the growing medical demand.
- Clinical Impact: The launch of the MAGiC catheter will not only promote the application of robotic technology in electrophysiology but also provide physicians with safer and more effective treatment options, further solidifying Stereotaxis's leadership in innovative medical technology.
Continue Reading